Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ImmunoGen, Inc.    IMGN   US45253H1014

IMMUNOGEN, INC. (IMGN)

14
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Sales16,435,559,9101112134
Operating income (EBITDA)--68,4-66,9-59,5-44,3-22,5
Operating profit (EBIT)-73,3-73,0-71,5-64,0-56,8-54,7
Pre-Tax Profit (EBT)-73,3-72,8----
Net income-73,3-72,8-71,4-62,5-58,7-59,1
EPS ( $)-0,95-0,87-0,83-0,73-0,61-0,49
Dividend per Share ( $)------
Yield------
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Debt------
Finance-19514282,691,248,2
Operating income (EBITDA)--68,4-66,9-59,5-44,3-22,5
Leverage
(Debt/EBITDA)
------
Capital Expenditure2,903,778,187,016,251,50
Book Value Per Share (BVPS)-1,44 $0,88 $0,62 $0,58 $0,12 $
Cash Flow per Share--0,72 $-0,63 $-0,56 $-0,39 $-
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Assessed data source :
© 2014 Thomson Reuters
Advertisement
Financial Ratios

Size 2015e 2016e
Capitalization 713 M$ -
Entreprise Value (EV) 630 M$ 622 M$
Valuation 2015e 2016e
PER (Price / EPS)
Capitalization / Revenue 7,06x 6,39x
EV / Revenue 6,24x 5,57x
EV / EBITDA -10,6x -14,0x
Yield (DPS / Price) - -
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) -63,4% -50,9%
operating Leverage (Delta EBIT / Delta Sales) 0,15x 1,07x
Net Margin (Net Profit / Revenue) -61,9% -52,6%
ROA (Net Profit / Asset) -67,1% -
ROE (Net Profit / Equities) -124% -105%
Rate of Dividend - -
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   6,95% 5,60%
Cash Flow / Sales (Taux d'autofinancement) -47,6% -30,2%
Capital Intensity (Assets / Sales) 0,92x -
Financial Leverage (Net Debt / EBITDA) 1,39x 2,06x
EPS & Dividend
Dynamic quotes  
ON
| OFF